您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > WHI-P154
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
WHI-P154
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
WHI-P154图片
CAS NO:211555-04-3
规格:98%
分子量:376.2
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
JAK3 inhibitor
CAS:211555-04-3
分子式:C16H14BrN3O3
分子量:376.2
纯度:98%
存储:Store at -20°C

Background:

WHI-P154 is an inhibitor of JAK3 with IC50 value of 1.8μM [1].


In vitro kinase assays show that WHI-P154 is not a specific inhibitor. Besides JAK3, it also inhibits many other kinases, including EGFR, ABL, LCK, SRC and VEGFR. WHI-P154 inhibits EGFR with IC50 value of 4nM. The specificity of WHI-P154 has not been shown in cell-based assays either [1].


WHI-P154 shows cytotoxicity against the U373 human glioblastoma cell line in vitro. This antitumor activity can be enhanced by conjugation to EGF. WHI-P154 also shows antitumor activity in a SCID mouse xenograft model of human glioblastoma [2].


参考文献:
[1] Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, Whipple DA, Doty JL, Sun J, Kent CR, Magnuson KS, Perregaux DG, Sawyer PS, Kudlacz EM. The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
[2] Narla RK, Liu XP, Myers DE, Uckun FM. 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res. 1998 Jun;4(6):1405-14.